Phase 4
Completed N=100
Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes
Source: ClinicalTrials.gov NCT02014740 ↗Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Mar 2018
Primary outcomePrimary: Echocardiographic Epicardial Fat Thickness — 9.6; 7.4; 6.8; 7.5 mm
◆ Published Evidence
Highly cited
242citations · ~27 / year
Liraglutide causes large and rapid epicardial fat reduction.
Summary
The purpose of this research study is to learn about the effect of Liraglutide, (Victoza®), on the fat surrounding the heart.Excessive amount of the fat around the heart is common in people with type 2 diabetes and can be associated with poor sugar control. Liraglutide is an injectable prescription medicine that can improve blood sugar control in adults with type 2 diabetes.
Linked Publications
-
Liraglutide causes large and rapid epicardial fat reduction.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Echocardiographic Epicardial Fat Thickness |
9.6; 7.4; 6.8; 7.5; 6.2; 6.9 | — |
Eligibility Criteria
Inclusion Criteria
- Type 2 diabetes, as defined by ADA criteria
- HbA1c 18 and < 65 years old
Exclusion Criteria
- • Known contra-indications to Liraglutide, such as previous history of pancreatitis or medullary thyroid carcinoma, personal or family history of MEN, in accordance with risks and safety information included in the latest updated Prescribing Information for Victoza®
- Type 1 diabetes, as defined by American Diabetes Association (ADA) criteria
- Insulin dependent or treated type 2 diabetes
- Current use of other injectable incretins
- History of diabetes ketoacidosis
- Advanced Chronic Kidney Disease, as defined by Glomerular Filtration Rate (GFR) < 30 mL/min/1.73m2
- Clinical signs or symptoms of New York Heart Association (NYHA) class III-IV heart failure
- Clinical or laboratory evidences of chronic active liver diseases
- Acute or chronic infective diseases
- Cancer or chemotherapy
- Current use of systemic corticosteroids or in the 3 months prior this study
- Known or suspected allergy to Liraglutide, excipients, or related products
- Pregnant, breast-feeding or the intention of becoming pregnant
- Females of childbearing potential who are not using adequate contraceptive methods
Data sourced from ClinicalTrials.gov (NCT02014740) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.